Cargando…
A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine
Influenza virus infects the host and transmits through the respiratory tract (i.e., the mouth and nose); therefore, the development of intranasal influenza vaccines that mimic the natural infection, coupled with an efficient mucosal adjuvant, is an attractive alternative to current parenteral vaccin...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230830/ https://www.ncbi.nlm.nih.gov/pubmed/35746644 http://dx.doi.org/10.3390/v14061174 |
_version_ | 1784735165859233792 |
---|---|
author | Feng, Huapeng Sun, Ruolin Song, Guanru Zhu, Shunfan Nie, Zhenyu Lin, Liming Yi, Ruonan Wu, Shixiang Wang, Genzhu He, Yulong Wang, Siquan Wang, Pei Wu, Li Shu, Jianhong |
author_facet | Feng, Huapeng Sun, Ruolin Song, Guanru Zhu, Shunfan Nie, Zhenyu Lin, Liming Yi, Ruonan Wu, Shixiang Wang, Genzhu He, Yulong Wang, Siquan Wang, Pei Wu, Li Shu, Jianhong |
author_sort | Feng, Huapeng |
collection | PubMed |
description | Influenza virus infects the host and transmits through the respiratory tract (i.e., the mouth and nose); therefore, the development of intranasal influenza vaccines that mimic the natural infection, coupled with an efficient mucosal adjuvant, is an attractive alternative to current parenteral vaccines. However, with the withdrawal of cholera toxin and Escherichia coli heat-labile endotoxin from clinical use due to side effects, there are no approved adjuvants for intranasal vaccines. Therefore, safe and effective mucosal adjuvants are urgently needed. Previously, we reported that one derivative of α-Galactosylceramide (α-GalCer), 7DW8-5, could enhance the protective efficacy of split influenza vaccine by injection administration. However, the mucosal adjuvanticity of 7DW8-5 is still unclear. In this study, we found that 7DW8-5 promotes the production of secret IgA antibodies and IgG antibodies and enhances the protective efficacy of the split influenza vaccine by intranasal administration. Furthermore, co-administration of 7DW8-5 with the split influenza vaccine significantly reduces the virus shedding in the upper and lower respiratory tract after lethal challenge. Our results demonstrate that 7DW8-5 is a novel mucosal adjuvant for the split influenza vaccine. |
format | Online Article Text |
id | pubmed-9230830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92308302022-06-25 A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine Feng, Huapeng Sun, Ruolin Song, Guanru Zhu, Shunfan Nie, Zhenyu Lin, Liming Yi, Ruonan Wu, Shixiang Wang, Genzhu He, Yulong Wang, Siquan Wang, Pei Wu, Li Shu, Jianhong Viruses Article Influenza virus infects the host and transmits through the respiratory tract (i.e., the mouth and nose); therefore, the development of intranasal influenza vaccines that mimic the natural infection, coupled with an efficient mucosal adjuvant, is an attractive alternative to current parenteral vaccines. However, with the withdrawal of cholera toxin and Escherichia coli heat-labile endotoxin from clinical use due to side effects, there are no approved adjuvants for intranasal vaccines. Therefore, safe and effective mucosal adjuvants are urgently needed. Previously, we reported that one derivative of α-Galactosylceramide (α-GalCer), 7DW8-5, could enhance the protective efficacy of split influenza vaccine by injection administration. However, the mucosal adjuvanticity of 7DW8-5 is still unclear. In this study, we found that 7DW8-5 promotes the production of secret IgA antibodies and IgG antibodies and enhances the protective efficacy of the split influenza vaccine by intranasal administration. Furthermore, co-administration of 7DW8-5 with the split influenza vaccine significantly reduces the virus shedding in the upper and lower respiratory tract after lethal challenge. Our results demonstrate that 7DW8-5 is a novel mucosal adjuvant for the split influenza vaccine. MDPI 2022-05-28 /pmc/articles/PMC9230830/ /pubmed/35746644 http://dx.doi.org/10.3390/v14061174 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Feng, Huapeng Sun, Ruolin Song, Guanru Zhu, Shunfan Nie, Zhenyu Lin, Liming Yi, Ruonan Wu, Shixiang Wang, Genzhu He, Yulong Wang, Siquan Wang, Pei Wu, Li Shu, Jianhong A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine |
title | A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine |
title_full | A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine |
title_fullStr | A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine |
title_full_unstemmed | A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine |
title_short | A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine |
title_sort | glycolipid α-galcer derivative, 7dw8-5 as a novel mucosal adjuvant for the split inactivated influenza vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230830/ https://www.ncbi.nlm.nih.gov/pubmed/35746644 http://dx.doi.org/10.3390/v14061174 |
work_keys_str_mv | AT fenghuapeng aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT sunruolin aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT songguanru aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT zhushunfan aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT niezhenyu aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT linliming aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT yiruonan aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wushixiang aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wanggenzhu aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT heyulong aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wangsiquan aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wangpei aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wuli aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT shujianhong aglycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT fenghuapeng glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT sunruolin glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT songguanru glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT zhushunfan glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT niezhenyu glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT linliming glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT yiruonan glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wushixiang glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wanggenzhu glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT heyulong glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wangsiquan glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wangpei glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT wuli glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine AT shujianhong glycolipidagalcerderivative7dw85asanovelmucosaladjuvantforthesplitinactivatedinfluenzavaccine |